Healthcare systems have had to adapt to evolving challenges in recent years, and in response, the pharmaceutical and biotechnology sectors have implemented different innovative pricing and reimbursement models. In an article for MedTech Strategist, we explore whether similar innovative reimbursement and contracting schemes might be developed for medical technologies and how the challenges they bring might be overcome.
CRA promotes 11 to vice president, strengthening expertise across the firm
“The achievements of our newly promoted Vice Presidents reflect the great year that CRA had in 2025 and reinforce my optimism in our future,” said CRA...